[MOU - NMDP IRB] An Open-Label, Single-Arm, Multicenter Study, of Combination anti-CD3/CD7 Immunotoxin (T-Guard) for Steroid-Refractory Acute Graft-versus-Host Disease
We are doing this study to see if T-Guard works to treat acute GVHD that doesn't get better with steroids. We want to know if T-Guard therapy will make your acute GVHD go away completely after 28 days.
Acute Graft Versus Host Disease
Allogeneic stem cell transplant
- 12 years or older.
- Previous allogeneic stem cell transplant using bone marrow, peripheral blood stem cells or cord blood.
Steroid refractory acute GVHD after allogeneic transplant.
- Prior treatment with steroids
12 - 120
Healthy Volunteers Needed
Duration of Participation
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com
National Institute of Health
National Heart, Lung and Blood Institute
National Cancer Institute